ImmunoPrecise Antibodies Ltd.

Victoria, A1 · CIK 0001715925 · Biotech · Public

Custom monoclonal antibodies and recombinant antibody therapeutics developed using proprietary antibody discovery and engineering platforms

immunopreciseantibodies.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.5M
4 Form D · Jul 2024
26 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$133,875
Private capital raisedForm D · SEC$7,571
Private capital raisedForm D · SEC$341,710
Private capital raisedForm D · SEC$2,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1897Cybele Microbiome Inc—$1.6M
1898Direct Biologics, LLC—$12M
1899Inograft Biotherapeutics——
1900ImmunoPrecise Antibodies Ltd.—$2.5M
1901SYNSHARK LLC—$213K
1902Blank! The Musical LLC—$550K
1903SEQLL, LLC—$2.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 16 related persons
  • Jennifer BathDirector · Executive Officer
  • Robert BeecroftDirector · Executive Officer
  • Robert BurkeDirector
  • Chris BuyseDirector
  • Guy ChampagneDirector
  • Thomas D'OrazioDirector · Executive Officer
  • James KuoDirector
  • Mitch LevineDirector
  • Ilse RoodnikExecutive Officer
  • Greg SmithDirector
  • Barry SpringerDirector
  • Kristin TaylorExecutive Officer
  • Natasha TsaiExecutive Officer
  • NATASHA TSAIExecutive Officer
  • Dawn WattieExecutive Officer
  • Dirk WittersDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.